- Home
- SKYE vs IMPP Comparison
SKYE vs IMPP Comparison
Compare SKYE & IMPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- IMPP
- Stock Information
- Founded
- SKYE 2012
- IMPP 1981
- Country
- SKYE United States
- IMPP Greece
- Employees
- SKYE N/A
- IMPP N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- IMPP Marine Transportation
- Sector
- SKYE Health Care
- IMPP Consumer Discretionary
- Exchange
- SKYE Nasdaq
- IMPP Nasdaq
- Market Cap
- SKYE 80.7M
- IMPP 95.7M
- IPO Year
- SKYE N/A
- IMPP N/A
- Fundamental
- Price
- SKYE $2.30
- IMPP $3.03
- Analyst Decision
- SKYE Buy
- IMPP
- Analyst Count
- SKYE 6
- IMPP 0
- Target Price
- SKYE $16.60
- IMPP N/A
- AVG Volume (30 Days)
- SKYE 237.9K
- IMPP 152.0K
- Earning Date
- SKYE 05-08-2025
- IMPP 05-23-2025
- Dividend Yield
- SKYE N/A
- IMPP N/A
- EPS Growth
- SKYE N/A
- IMPP N/A
- EPS
- SKYE N/A
- IMPP 1.21
- Revenue
- SKYE N/A
- IMPP $138,368,325.00
- Revenue This Year
- SKYE N/A
- IMPP $3.05
- Revenue Next Year
- SKYE N/A
- IMPP $47.92
- P/E Ratio
- SKYE N/A
- IMPP $2.50
- Revenue Growth
- SKYE N/A
- IMPP N/A
- 52 Week Low
- SKYE $1.14
- IMPP $2.12
- 52 Week High
- SKYE $12.11
- IMPP $4.55
- Technical
- Relative Strength Index (RSI)
- SKYE 57.25
- IMPP 71.03
- Support Level
- SKYE $1.96
- IMPP $2.73
- Resistance Level
- SKYE $2.28
- IMPP $3.00
- Average True Range (ATR)
- SKYE 0.23
- IMPP 0.16
- MACD
- SKYE 0.02
- IMPP 0.03
- Stochastic Oscillator
- SKYE 86.89
- IMPP 94.45
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.